Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Sarepta Therapeutics, Inc.”

102 pharma patents match "Sarepta Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 102
Index total 30,257
Page 2 / 5

Quick answer

This filtered view shows 102 pharmaceutical patents matching "Sarepta Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

102 results for “Sarepta Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 11208655

    Functionally-modified oligonucleotides and subunits thereof

    Sarepta Therapeutics, Inc. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted
  2. US 11097011

    Peptide oligonucleotide conjugates

    Sarepta Therapeutics, Inc. · Granted Aug 24, 2021 · Expires Aug 19, 2041

    granted
  3. US 11071749

    Oligonucleotide analogues targeting human LMNA

    Sarepta Therapeutics, Inc. · Granted Jul 27, 2021 · Expires Jul 22, 2041

    granted
  4. US 11060089

    Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene

    Sarepta Therapeutics, Inc. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  5. US 11020417

    Methods and compounds for treatment of lymphocyte-related diseases and conditions

    Sarepta Therapeutics, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  6. US 11015200

    Antisense-induced exon exclusion in myostatin

    Sarepta Therapeutics, Inc. · Granted May 25, 2021 · Expires May 20, 2041

    granted
  7. US 11000600

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted May 11, 2021 · Expires May 6, 2041

    granted
  8. US 10927378

    Compound and method for treating myotonic dystrophy

    Sarepta Therapeutics, Inc. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted
  9. US 10905782

    Compositions for enhancing transport of molecules into cells

    Sarepta Therapeutics, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  10. US 10905709

    Modified antisense oligomers for exon inclusion in spinal muscular atrophy

    Sarepta Therapeutics, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  11. US 10907154

    Exon skipping compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  12. US 10888578

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Jan 12, 2021 · Expires Jan 7, 2041

    granted
  13. US 10849917

    Antisense-induced exon exclusion in type VII collagen

    Sarepta Therapeutics, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  14. US 10781450

    Antisense molecules and methods for treating pathologies

    Sarepta Therapeutics, Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted
  15. US 10765760

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Sep 8, 2020 · Expires Sep 3, 2040

    granted
  16. US 10760078

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Sarepta Therapeutics, Inc. · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted
  17. US 10758629

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted
  18. US 10675356

    Peptide oligonucleotide conjugates

    Sarepta Therapeutics, Inc. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  19. US 10626396

    Antisense composition and method for treating muscle atrophy

    Sarepta Therapeutics, Inc. · Granted Apr 21, 2020 · Expires Apr 16, 2040

    granted
  20. US 10577605

    Induced exon inclusion in spinal muscle atrophy

    Sarepta Therapeutics, Inc. · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  21. US 10533174

    Splice-region antisense composition and method

    Sarepta Therapeutics, Inc. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  22. US 10487326

    Peptide oligonucleotide conjugates

    Sarepta Therapeutics, Inc. · Granted Nov 26, 2019 · Expires Nov 21, 2039

    granted
  23. US 10479996

    Antisense antiviral compound and method for treating ss/RNA viral infection

    Sarepta Therapeutics, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  24. US 10364431

    Compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted